Medtronic PLC vs Direxion Daily FTSE China Bull 3x Shares — how do they compare? Medtronic PLC trades at $90.84 (market cap $116.07B), while Direxion Daily FTSE China Bull 3x Shares trades at $29.01. The key difference: Medtronic PLC pays a 3.18% dividend while Direxion Daily FTSE China Bull 3x Shares pays none, and Medtronic PLC is trading nearer its 52-week high, Direxion Daily FTSE China Bull 3x Shares nearer its low. Which is the better fit depends on your goals.
| MDT | YINN | |
|---|---|---|
Market Cap | $116.07B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $105.35 | $56.62 |
52-Week Low | $73.75 | $21.45 |
Enterprise Value | $134.82B | — |
Dividend Yield | 3.18% | — |
Signals from Pluang's Aura AI — not financial advice
Medtronic (MDT) trades at $90.70, up 1.44% with strong technical momentum and bullish moving average signals. The company demonstrates solid fundamentals with consistent earnings beats, including Q1 2026 EPS of $1.55 beating expectations of $1.54. Revenue growth accelerated to $33.54 billion in 2025 with improving profit margins of 13.2%. Recent positive developments include new product approvals and institutional accumulation, though RSI levels suggest potential near-term overbought conditions.
The outlook remains positive with analyst consensus targeting $98.75 (8.9% upside) and no sell ratings. Key opportunities include robotic surgery platform expansion and cardiac ablation growth, while risks involve rising debt levels and competitive pressures. The stock offers dividend stability with a $0.72 upcoming payment, making it attractive for income-focused investors seeking medical technology exposure.
YINN, a leveraged ETF tracking the FTSE China Bull 3x strategy, trades at $28.93, down 10.43% in 24 hours amid broad bearish technical signals. The fund lacks traditional financial ratios due to its structure, with a dividend of $0.21 scheduled for June 2026. Recent news highlights China's economic stimulus and AI investments, but geopolitical tensions and regulatory risks persist.
Outlook remains cautious due to leverage amplifying volatility; opportunities exist if Chinese equities rebound, but risks include US-China friction and economic slowdowns. Investors should weigh the ETF's high-risk profile against potential gains from China's tech growth initiatives.
Trailing returns across standard periods
Latest headlines on both assets
One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →YINN is a leveraged ETF that seeks daily investment results, before fees and expenses, of 300% (3x) of the daily performance of the FTSE China 50 Index. It is a tactical instrument designed for sophisticated traders seeking to magnify short-term bullish views on large-cap Chinese equities, primarily those trading on the Hong Kong Stock Exchange.
Read more on YINN →